References
Abbadie C, McManus OB, Sun SY, Bugianesi RM, Dai G, Haedo RJ, et
al. (2010). Analgesic effects of a substituted N-triazole oxindole
(TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. J
Pharmacol Exp Ther 334: 545-555.
Alexander SP, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters
JA, et al. (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G
protein-coupled receptors. British journal of pharmacology 178 Suppl
1: S27-s156.
Aparoy P, Reddy KK, & Reddanna P (2012). Structure and ligand based
drug design strategies in the development of novel 5- LOX inhibitors.
Curr Med Chem 19: 3763-3778.
Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, et
al. (2006). EFNS guidelines on pharmacological treatment of neuropathic
pain. Eur J Neurol 13: 1153-1169.
Basbaum AI, Bautista DM, Scherrer G, & Julius D (2009). Cellular and
molecular mechanisms of pain. Cell 139: 267-284.
Bauer CS, Rahman W, Tran-van-Minh A, Lujan R, Dickenson AH, & Dolphin
AC (2010). The anti-allodynic alpha(2)delta ligand pregabalin inhibits
the trafficking of the calcium channel alpha(2)delta-1 subunit to
presynaptic terminals in vivo. Biochem Soc Trans 38: 525-528.
Bell TJ, Thaler C, Castiglioni AJ, Helton TD, & Lipscombe D (2004).
Cell-specific alternative splicing increases calcium channel current
density in the pain pathway. Neuron 41: 127-138.
Bellampalli SS, Ji Y, Moutal A, Cai S, Wijeratne EMK, Gandini MA,
et al. (2019). Betulinic acid, derived from the desert lavender Hyptis
emoryi, attenuates paclitaxel-, HIV-, and nerve injury-associated
peripheral sensory neuropathy via block of N- and T-type calcium
channels. Pain 160: 117-135.
Bickerton GR, Paolini GV, Besnard J, Muresan S, & Hopkins AL (2012).
Quantifying the chemical beauty of drugs. Nat Chem 4: 90-98.
Brittain JM, Chen L, Wilson SM, Brustovetsky T, Gao X, Ashpole NM,
et al. (2011a). Neuroprotection against traumatic brain injury by a
peptide derived from the collapsin response mediator protein 2 (CRMP2).
J Biol Chem 286: 37778-37792.
Brittain JM, Duarte DB, Wilson SM, Zhu W, Ballard C, Johnson PL,
et al. (2011b). Suppression of inflammatory and neuropathic pain by
uncoupling CRMP-2 from the presynaptic Ca(2)(+) channel complex. Nat Med
17: 822-829.
Brittain JM, Piekarz AD, Wang Y, Kondo T, Cummins TR, & Khanna R
(2009). An atypical role for collapsin response mediator protein 2
(CRMP-2) in neurotransmitter release via interaction with presynaptic
voltage-gated calcium channels. J Biol Chem 284: 31375-31390.
Brittain JM, Wang Y, Eruvwetere O, & Khanna R (2012). Cdk5-mediated
phosphorylation of CRMP-2 enhances its interaction with CaV2.2. FEBS
Lett 586: 3813-3818.
Bruckdorfer T, Marder O, & Albericio F (2004). From production of
peptides in milligram amounts for research to multi-tons quantities for
drugs of the future. Curr Pharm Biotechnol 5: 29-43.
Brustovetsky T, Pellman JJ, Yang XF, Khanna R, & Brustovetsky N (2014).
Collapsin response mediator protein 2 (CRMP2) interacts with
N-methyl-D-aspartate (NMDA) receptor and Na+/Ca2+ exchanger and
regulates their functional activity. The Journal of biological chemistry
289: 7470-7482.
Cai S, Shan Z, Zhang Z, Moutal A, & Khanna R (2019). Activity of T-type
calcium channels is independent of CRMP2 in sensory neurons. Channels
(Austin) 13: 147-152.
Case DA, Ben-Shalom IY, Brozell SR, Cerutti DS, Cheatham TE, III,
Cruzeiro VWD, et al. (2018). AMBER 2018Univesity of California,
San Francisco.
Chaplan SR, Bach FW, Pogrel JW, Chung JM, & Yaksh TL (1994).
Quantitative assessment of tactile allodynia in the rat paw. J Neurosci
Methods 53: 55-63.
Chi XX, Schmutzler BS, Brittain JM, Wang Y, Hingtgen CM, Nicol GD,
et al. (2009). Regulation of N-type voltage-gated calcium channels
(Cav2.2) and transmitter release by collapsin response mediator
protein-2 (CRMP-2) in sensory neurons. J Cell Sci 122:4351-4362.
Choe W, Messinger RB, Leach E, Eckle VS, Obradovic A, Salajegheh
R, et al. (2011). TTA-P2 is a potent and selective blocker of
T-type calcium channels in rat sensory neurons and a novel
antinociceptive agent. Mol Pharmacol 80: 900-910.
Cizkova D, Marsala J, Lukacova N, Marsala M, Jergova S, Orendacova
J, et al. (2002). Localization of N-type Ca2+ channels in the rat
spinal cord following chronic constrictive nerve injury. Exp Brain Res
147: 456-463.
Decosterd I, & Woolf CJ (2000). Spared nerve injury: an animal model of
persistent peripheral neuropathic pain. Pain 87: 149-158.
Doggrell SA (2004). Intrathecal ziconotide for refractory pain. Expert
Opin Investig Drugs 13: 875-877.
Dustrude ET, Moutal A, Yang X, Wang Y, Khanna M, & Khanna R (2016).
Hierarchical CRMP2 posttranslational modifications control NaV1.7
function. Proc Natl Acad Sci U S A 113: E8443-E8452.
Dustrude ET, Perez-Miller S, Francois-Moutal L, Moutal A, Khanna M, &
Khanna R (2017). A single structurally conserved SUMOylation site in
CRMP2 controls NaV1.7 function. Channels (Austin) 11: 316-328.
Dustrude ET, Wilson SM, Ju W, Xiao Y, & Khanna R (2013). CRMP2 protein
SUMOylation modulates NaV1.7 channel trafficking. The Journal of
biological chemistry 288: 24316-24331.
Evans AR, Nicol GD, & Vasko MR (1996). Differential regulation of
evoked peptide release by voltage-sensitive calcium channels in rat
sensory neurons. Brain Res 712: 265-273.
Evoy KE, Peckham AM, Covvey JR, & Tidgewell KJ (2021). Gabapentinoid
Pharmacology in the Context of Emerging Misuse Liability. Journal of
clinical pharmacology 61 Suppl 2: S89-s99.
Feng ZP, Hamid J, Doering C, Bosey GM, Snutch TP, & Zamponi GW (2001).
Residue Gly1326 of the N-type calcium channel alpha 1B subunit controls
reversibility of omega-conotoxin GVIA and MVIIA block. J Biol Chem
276: 15728-15735.
Fischer G, Pan B, Vilceanu D, Hogan QH, & Yu H (2014). Sustained relief
of neuropathic pain by AAV-targeted expression of CBD3 peptide in rat
dorsal root ganglion. Gene Ther 21: 44-51.
Fosgerau K, & Hoffmann T (2015). Peptide therapeutics: current status
and future directions. Drug Discov Today 20: 122-128.
Francois-Moutal L, Wang Y, Moutal A, Cottier KE, Melemedjian OK, Yang
X, et al. (2015). A membrane-delimited N-myristoylated CRMP2
peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory
and postoperative pain behaviors. Pain 156: 1247-1264.
Giglio CA, Defino HL, da-Silva CA, de-Souza AS, & Del Bel EA (2006).
Behavioral and physiological methods for early quantitative assessment
of spinal cord injury and prognosis in rats. Braz J Med Biol Res
39: 1613-1623.
Gomez K, Tang C, Tan B, Perez-Miller S, Ran D, Loya S, et al.(2022). Stereospecific Effects of Benzimidazolonepiperidine Compounds on
T-Type Ca(2+) Channels and Pain. ACS Chem Neurosci.
Goshima Y, Nakamura F, Strittmatter P, & Strittmatter SM (1995).
Collapsin-induced growth cone collapse mediated by an intracellular
protein related to UNC-33. Nature 376: 509-514.
Götz AW, Williamson MJ, Xu D, Poole D, Le Grand S, & Walker RC (2012).
Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs.
1. Generalized Born. J Chem Theory Comput 8: 1542-1555.
Gupta M, Lee HJ, Barden CJ, & Weaver DF (2019). The Blood-Brain Barrier
(BBB) Score. J Med Chem 62: 9824-9836.
Hatakeyama S, Wakamori M, Ino M, Miyamoto N, Takahashi E, Yoshinaga
T, et al. (2001). Differential nociceptive responses in mice
lacking the alpha(1B) subunit of N-type Ca(2+) channels. Neuroreport
12: 2423-2427.
Heinke B, Balzer E, & Sandkuhler J (2004). Pre- and postsynaptic
contributions of voltage-dependent Ca2+ channels to nociceptive
transmission in rat spinal lamina I neurons. Eur J Neurosci 19:103-111.
Hendrich J, Van Minh AT, Heblich F, Nieto-Rostro M, Watschinger K,
Striessnig J, et al. (2008). Pharmacological disruption of
calcium channel trafficking by the alpha2delta ligand gabapentin.
Proceedings of the National Academy of Sciences of the United States of
America 105: 3628-3633.
Hoppanova L, & Lacinova L (2022). Voltage-dependent CaV3.2 and CaV2.2
channels in nociceptive pathways. Pflugers Arch 474: 421-434.
Inagaki N, Chihara K, Arimura N, Menager C, Kawano Y, Matsuo N, et
al. (2001). CRMP-2 induces axons in cultured hippocampal neurons. Nat
Neurosci 4: 781-782.
Irwin S, Houde RW, Bennett DR, Hendershot LC, & Seevers MH (1951). The
effects of morphine methadone and meperidine on some reflex responses of
spinal animals to nociceptive stimulation. J Pharmacol Exp Ther
101: 132-143.
Ji Y, Hu Y, Ren J, Khanna R, Yao Y, Chen Y, et al. (2019).
CRMP2-derived peptide ST2-104 (R9-CBD3) protects SH-SY5Y neuroblastoma
cells against Abeta25-35-induced neurotoxicity by inhibiting the
pCRMP2/NMDAR2B signaling pathway. Chem Biol Interact 305:28-39.
Ju W, Li Q, Allette YM, Ripsch MS, White FA, & Khanna R (2013).
Suppression of pain-related behavior in two distinct rodent models of
peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide. J
Neurochem 124: 869-879.
Khanna R, Yu J, Yang X, Moutal A, Chefdeville A, Gokhale V, et
al. (2019). Targeting the CaValpha-CaVbeta interaction yields an
antagonist of the N-type CaV2.2 channel with broad antinociceptive
efficacy. Pain 160: 1644-1661.
Khanna R, Zougman A, & Stanley EF (2007). A proteomic screen for
presynaptic terminal N-type calcium channel (CaV2.2) binding partners. J
Biochem Mol Biol 40: 302-314.
Kim C, Jun K, Lee T, Kim SS, McEnery MW, Chin H, et al. (2001).
Altered nociceptive response in mice deficient in the alpha(1B) subunit
of the voltage-dependent calcium channel. Mol Cell Neurosci 18:235-245.
Koes DR, & Camacho CJ (2012). ZINCPharmer: pharmacophore search of the
ZINC database. Nucleic Acids Res 40: W409-414.
Kozakov D, Clodfelter KH, Vajda S, & Camacho CJ (2005). Optimal
clustering for detecting near-native conformations in protein docking.
Biophys J 89: 867-875.
Kuehn BM (2022). Gabapentin Increasingly Implicated in Overdose Deaths.
JAMA 327: 2387.
Li L, Cao XH, Chen SR, Han HD, Lopez-Berestein G, Sood AK, et al.(2012). Up-regulation of Cavbeta3 subunit in primary sensory neurons
increases voltage-activated Ca2+ channel activity and nociceptive input
in neuropathic pain. J Biol Chem 287: 6002-6013.
Lipinski CA (2004). Lead- and drug-like compounds: the rule-of-five
revolution. Drug Discov Today Technol 1: 337-341.
Ludwig A, Flockerzi V, & Hofmann F (1997). Regional expression and
cellular localization of the alpha1 and beta subunit of high
voltage-activated calcium channels in rat brain. J Neurosci 17:1339-1349.
Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, &
Simmerling C (2015). ff14SB: Improving the Accuracy of Protein Side
Chain and Backbone Parameters from ff99SB. J Chem Theory Comput
11: 3696-3713.
Mintz IM, Venema VJ, Swiderek KM, Lee TD, Bean BP, & Adams ME (1992).
P-type calcium channels blocked by the spider toxin omega-Aga-IVA.
Nature 355: 827-829.
Moutal A, Li W, Wang Y, Ju W, Luo S, Cai S, et al. (2018).
Homology-guided mutational analysis reveals the functional requirements
for antinociceptive specificity of collapsin response mediator protein
2-derived peptides. Br J Pharmacol 175: 2244-2260.
Murakami M, Fleischmann B, De Felipe C, Freichel M, Trost C, Ludwig
A, et al. (2002). Pain perception in mice lacking the beta3
subunit of voltage-activated calcium channels. J Biol Chem 277:40342-40351.
Newcomb R, Szoke B, Palma A, Wang G, Chen X, Hopkins W, et al.(1998). Selective peptide antagonist of the class E calcium channel from
the venom of the tarantula Hysterocrates gigas. Biochemistry
37: 15353-15362.
Nieto-Rostro M, Ramgoolam K, Pratt WS, Kulik A, & Dolphin AC (2018).
Ablation of alpha2delta-1 inhibits cell-surface trafficking of
endogenous N-type calcium channels in the pain pathway in vivo. Proc
Natl Acad Sci U S A 115: E12043-E12052.
Nowycky MC, Fox AP, & Tsien RW (1985). Three types of neuronal calcium
channel with different calcium agonist sensitivity. Nature 316:440-443.
Perez JJ (2018). Designing Peptidomimetics. Curr Top Med Chem
18: 566-590.
Piekarz AD, Due MR, Khanna M, Wang B, Ripsch MS, Wang R, et al.(2012). CRMP-2 peptide mediated decrease of high and low
voltage-activated calcium channels, attenuation of nociceptor
excitability, and anti-nociception in a model of AIDS therapy-induced
painful peripheral neuropathy. Mol Pain 8: 54.
Rajamani D, Thiel S, Vajda S, & Camacho CJ (2004). Anchor residues in
protein-protein interactions. Proc Natl Acad Sci U S A 101:11287-11292.
Richards MW, Butcher AJ, & Dolphin AC (2004). Ca2+ channel
beta-subunits: structural insights AID our understanding. Trends
Pharmacol Sci 25: 626-632.
Ripsch MS, Ballard CJ, Khanna M, Hurley JH, White FA, & Khanna R
(2012). A PEPTIDE UNCOUPLING CRMP-2 FROM THE PRESYNAPTIC Ca(2+) CHANNEL
COMPLEX DEMONSTRATES EFFICACY IN ANIMAL MODELS OF MIGRAINE AND AIDS
THERAPY-INDUCED NEUROPATHY. Transl Neurosci 3: 1-8.
Salomon-Ferrer R, Götz AW, Poole D, Le Grand S, & Walker RC (2013).
Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs.
2. Explicit Solvent Particle Mesh Ewald. J Chem Theory Comput
9: 3878-3888.
Scott VE, De Waard M, Liu H, Gurnett CA, Venzke DP, Lennon VA, et
al. (1996). Beta subunit heterogeneity in N-type Ca2+ channels. J Biol
Chem 271: 3207-3212.
Shao PP, Ye F, Chakravarty PK, Varughese DJ, Herrington JB, Dai G,
et al. (2012). Aminopiperidine sulfonamide Cav2.2 channel inhibitors
for the treatment of chronic pain. J Med Chem 55: 9847-9855.
Smith AJ (2015). New horizons in therapeutic antibody discovery:
opportunities and challenges versus small-molecule therapeutics. J
Biomol Screen 20: 437-453.
Sterling T, & Irwin JJ (2015). ZINC 15–Ligand Discovery for
Everyone. J Chem Inf Model 55: 2324-2337.
Striessnig J (2018). Getting a handle on Ca(V)2.2 (N-type) voltage-gated
Ca(2+) channels. Proc Natl Acad Sci U S A 115: 12848-12850.
Sutton KG, Martin DJ, Pinnock RD, Lee K, & Scott RH (2002). Gabapentin
inhibits high-threshold calcium channel currents in cultured rat dorsal
root ganglion neurones. Br J Pharmacol 135: 257-265.
Welling A, Bosse E, Cavalie A, Bottlender R, Ludwig A, Nastainczyk
W, et al. (1993). Stable co-expression of calcium channel alpha
1, beta and alpha 2/delta subunits in a somatic cell line. J Physiol
471: 749-765.
Xie JY, Chew LA, Yang X, Wang Y, Qu C, Wang Y, et al. (2016).
Sustained relief of ongoing experimental neuropathic pain by a CRMP2
peptide aptamer with low abuse potential. Pain 157: 2124-2140.
Yaksh TL, & Rudy TA (1976). Chronic catheterization of the spinal
subarachnoid space. Physiol Behav 17: 1031-1036.
Yang J, Xie MX, Hu L, Wang XF, Mai JZ, Li YY, et al. (2018).
Upregulation of N-type calcium channels in the soma of uninjured dorsal
root ganglion neurons contributes to neuropathic pain by increasing
neuronal excitability following peripheral nerve injury. Brain Behav
Immun 71: 52-65.
Yeh CY, Ye Z, Moutal A, Gaur S, Henton AM, Kouvaros S, et al.(2019). Defining the Kv2.1-syntaxin molecular interaction identifies a
first-in-class small molecule neuroprotectant. Proc Natl Acad Sci U S A
116: 15696-15705.
Yu H, Shin SM, Xiang H, Chao D, Cai Y, Xu H, et al. (2019a).
AAV-encoded Ca(V)2.2 peptide aptamer CBD3A6K for primary sensory
neuron-targeted treatment of established neuropathic pain. Gene Ther
26: 308-323.
Yu J, Moutal A, Dorame A, Bellampalli SS, Chefdeville A, Kanazawa
I, et al. (2019b). Phosphorylated CRMP2 Regulates Spinal
Nociceptive Neurotransmission. Mol Neurobiol 56: 5241-5255.
Zamponi GW (2003). Regulation of presynaptic calcium channels by
synaptic proteins. J Pharmacol Sci 92: 79-83.
Zamponi GW, Striessnig J, Koschak A, & Dolphin AC (2015). The
Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium
Channels and Their Future Therapeutic Potential. Pharmacological reviews
67: 821-870.
Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, et
al. (2018). Tuning microtubule dynamics to enhance cancer therapy by
modulating FER-mediated CRMP2 phosphorylation. Nat Commun 9:476.